C4X Discovery Holdings PLC Total Voting Rights (4683H)
04 August 2021 - 2:14AM
UK Regulatory
TIDMC4XD
RNS Number : 4683H
C4X Discovery Holdings PLC
03 August 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Total Voting Rights
3 August 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, announces that pursuant to its
block admission facility, details of which were announced on 1 July
2021, it has recently issued 1,100,000 ordinary shares of GBP0.01
each in the Company ("Ordinary Shares") in satisfaction of the
exercise of warrants. The new Ordinary Shares rank pari passu with
the Company's existing shares.
In accordance with DTR 5.6.1 of the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules, as of 3
August 2021, the Company has 227,812,697 Ordinary Shares in issue.
There are no shares held in treasury. The total number of voting
rights in the Company is therefore 227,812,697.
The above figure of 227,812,697 may be used by shareholders in
the Company as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
neurodegeneration, oncology and addictive disorders . Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio. For more information visit
us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDKNBDABKDNFK
(END) Dow Jones Newswires
August 03, 2021 12:14 ET (16:14 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024